Experimental hepatitis B drug may offer ‘functional cure’ for some patients

Aetherion Therapeutics has announced breakthrough data from its Phase 2b Clinical Trials for VGL-1200, an experimental Hepatitis B (HBV) drug, demonstrating a functional cure in 18% of patients with chronic HBV. This first-of-its-kind RNA Interference (RNAi) therapeutic appears to allow for sustained viral remission and HBsAg Seroclearance, enabling patients to discontinue lifelong Antiviral Therapy without viral rebound. The implications are profound for the estimated 296 million people living with chronic HBV globally, who currently face a lifetime of Nucleos(t)ide Analogs to manage the virus, often failing to prevent progression to Liver Cirrhosis or hepatocellular carcinoma. This data, which shows VGL-1200 significantly outperforms existing treatment regimens in achieving HBsAg seroclearance, redefines the competitive landscape, challenging major players like Gilead Sciences who have long dominated the antiviral market with incremental advances. Aetherion plans to fast-track VGL-1200 into pivotal Phase 3 trials by late 2026, setting the stage for a potential market entry by 2029 if regulatory hurdles are cleared swiftly. The biotech firm's stock surged over 40% on the news, signaling strong investor confidence in a drug that could transition HBV management from chronic suppression to curative intervention, a paradigm shift for global public health.